Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor‐α to interleukin‐17A inhibitor

2019 ◽  
Vol 181 (3) ◽  
pp. 624-626 ◽  
Author(s):  
P. Gisondi ◽  
D. Geat ◽  
L. Idolazzi ◽  
G. Girolomoni
Keyword(s):  
Psoriatic Arthritis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Α ◽  
Interleukin 17A ◽  
Factor Α ◽  
Necrosis Factor

Scintigraphy for detecting tumour necrosis factor-α on the skin of patients with psoriatic arthritis

2016 ◽  
Vol 46 (5) ◽  
pp. 377-380 ◽  
Author(s):  
SAL de Souza ◽  
V Nentzinsky ◽  
CCM do Carmo ◽  
L Roimicher ◽  
LMB da Fonseca ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Hepatoprotective effect of tumour necrosis factor α blockade in psoriatic arthritis: a cross-sectional study

2009 ◽  
Vol 69 (6) ◽  
pp. 1148-1150 ◽  
Author(s):  
Michael Seitz ◽  
Stephan Reichenbach ◽  
Burkhard Möller ◽  
Marcel Zwahlen ◽  
Peter M Villiger ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Liver Fibrosis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Transient Elastography ◽  
Liver Steatosis ◽  
Tumour Necrosis Factor Α ◽  
Factor Α ◽  
The Impact ◽  
Necrosis Factor

ObjectiveTo evaluate the impact of tumour necrosis factor α (TNFα) blockers on the presence of liver fibrosis in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with methotrexate (MTX).MethodsParticipants were consecutive patients with RA and PsA who had undergone MTX treatment for at least 1 year ± TNF blockade for over 6 months. Liver fibrosis was assessed using non-invasive transient elastography (FibroScan). Regression models were used to compare FibroScan values of patients with RA and patients with PsA receiving TNFα blockers with those who were not.ResultsFibroScan assessments were performed on 51 patients with RA and 43 patients with PsA. Compared to patients with RA, those with PsA were predominantly young men, received lower cumulative dosages of MTX and exhibited a higher incidence of liver steatosis and hyperlipidaemia. An abnormal result was observed in 7.1% of the anti-TNFα-naïve and in 13% of the anti-TNFα-treated patients in the RA group and in 30% of the anti-TNFα-naïve and 4.3% of the anti-TNFα-treated patients in the PsA group (OR=0.11, 95% CI 0.02 to 0.98). Results of the PsA group were robust when adjusted for baseline characteristics.ConclusionThe results suggest a protective effect of TNFα inhibitors against the development of liver fibrosis in patients with PsA.

scholarly journals The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries

Rheumatology ◽  
2016 ◽  
Vol 55 (12) ◽  
pp. 2191-2199 ◽  
Author(s):  
Pil Højgaard ◽  
Bente Glintborg ◽  
Lars Erik Kristensen ◽  
Bjorn Gudbjornsson ◽  
Thorvardur Jon Love ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Tumour Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor

Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: A twelve-year “real life” experience

2015 ◽  
Vol 82 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Anne-Sophie Soubrier ◽  
Peggy Bele-Philippe ◽  
Bernard Cortet ◽  
Nassima Ramdane-Sebbane ◽  
Marie-Astrid Bacle-Boutry ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Treatment Response ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Life Experience ◽  
Real Life ◽  
Tumour Necrosis Factor Α ◽  
Drug Survival ◽  
Factor Α ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document